多西他赛伊立替康联合替吉奥用于晚期胃癌患者的疗效对比  

Comparison on Efficacy of Docetaxel, Irinotidine and Tiggio in Patients with Advanced Gastric Cancer

作　　者：王文明 段爱雄[1] 江启安[1] 汪志求[1] WANG Wenming;DUAN Aixiong;JIANG Qi'an(Anqing Hospital Affiliated to Anhui Medical University,Anhui Anqing 246003,China)

机构地区：[1]安徽医科大学附属安庆医院肿瘤内科

出　　处：《河北医学》2020年第1期158-161,共4页Hebei Medicine

基　　金：安徽省自然科学基金项目,(编号:1805026PF169)

摘　　要：目的: 探究多西他赛联合替吉奥与伊立替康联合替吉奥治疗晚期胃癌患者的临床疗效,并分析其安全性。 方法: 选取2013年9月到2018年4月之间我院肿瘤内科收治的使用多西他赛联合替吉奥进行化疗的晚期胃癌患者35例为实验组,接受伊立替康联合替吉奥治疗的患者25例为对照组。比较两组化疗后的疾病控制率及毒性反应的情况;评估多西他赛、伊立替康分别联合替吉奥用于晚期胃癌患者的临床价值。 结果: 实验组的肿瘤缓解率和控制率分别为34.29%、71.43%,对照组为36%、72%,两组比较差异不具有统计学意义(χ 2=0.019、0.002,P>0.05);化疗后两组毒性反应主要包括白细胞减少、血小板减少、恶心呕吐、脱发、神经毒性以及手足综合征等,且各类反应以0~Ⅱ度为主,差异均不具有统计学意义(P>0.05)。 结论: 多西他赛联合替吉奥与伊立替康联合替吉奥均能有效控制肿瘤患者病情的发展速度,减少毒性反应发生情况,且两者疗效相当,毒性反应患者可耐受,值得在临床推广使用。Objective: To investigate the clinical efficacy and safety of docetaxel combined with irinotecan and irinotecan combined with teggio in patients with advanced gastric cancer. Methods: 35 patients with advanced gastric cancer receiving chemotherapy with docetaxel combined with tiggio in the department of oncology of our hospital between September 2013 and April 2018 were selected as the experimental group, and 25 patients receiving irinotecan combined with tiggio as the control group. The disease control rate and toxicity reaction after chemotherapy were compared between the two groups. The clinical value of docetaxel and irinotidine combined with teggio in patients with advanced gastric cancer were evaluated. Results: The tumor remission rate and control rate of the experimental group were 34.29% and 71.43%, respectively, while those of the control group were 36% and 72%. The difference between the two groups was not statistically significant (χ 2=0.019, 0.002, P>0.05). After chemotherapy toxicity of two groups of reactions including leukopenia, thrombocytopenia, nausea and vomiting, hair loss, neurotoxicity, and extremities syndrome, etc., and all kinds of reaction is given priority to with 0 ~ Ⅱ degrees, differences were not statistically significant (P>0.05). Conclusion: Docetaxel combined with tegeor and irinotecan combined with tegeor can effectively control the development speed of cancer patients, reduce the occurrence of toxic reactions, and both of them have the same effect, and the patients with toxic reactions can tolerate, which is worthy of clinical application.

关 键 词：晚期胃癌 多西他赛 伊立替康 替吉奥 

分 类 号：R735.2[医药卫生—肿瘤]